Uncategorized

12/30 Update to COVID-19 mAb (REGEN-COV) Restrictions

Read Time: 1 min

As you may be aware, the Department of Health and Human Services has placed a pause on the allocation of REGEN-COV and bamlanivimab/etesevimab based on data indicating they are unlikely to retain activity against the Omicron variant. We will not obtain any additional shipments of either COVID-19 monoclonal antibody (mAb) at this time. A request has been placed for sotrovimab, but exact allocation and arrival time is currently unknown.  

Based on patient volume and current inventory, the Kettering Health Pharmacy and Therapeutics Committee has approved changes to the COVID-19 monoclonal antibody (mAb) restrictions for both hospital and infusion center use

  • Two (2) risk factors are necessary to meet criteria for use (formerly one (1)). 
    • Pregnancy is an exception and is a single qualifying risk factor.
  • Restricted to treatment only. Kettering Health will no longer utilize monoclonal antibody for post-exposure prophylaxis (PEP) (updated 12/29/2021). 

Changes to EPIC referral forms and order panels will be forthcoming. 

Please consider the following when prescribing COVID-19 mAbs: 

  • Kettering Health estimates a 7-day supply on hand based on current inventory and usage. 
  • Be advised high volume of orders may cause delays in treatment and appointments at the Kettering Health COVID-19 Infusion Center.
  • Practitioners should counsel patients on the lack of efficacy of these agents against the Omicron variant 

Please see this form for complete list of requirements for COVID-19 monoclonal antibody use.  

We will continue to reevaluate this decision at regular intervals and provide updates to these restrictions as appropriate.  

December 30, 2021
ABOUT K-NEWS

Kettering Health employees’ hub for system updates, stories about our people, events, and more.